Publication | Open Access

Doxorubicin-loaded nanoparticles for patients with advanced hepatocellular carcinoma after sorafenib treatment failure (RELIVE): a phase 3 randomised controlled trial

NanoparticlesNanomedicineSorafenib Treatment FailureOncologyHepatologyEngineeringTherapeutic NanomaterialsMedicineNano-drug DeliveryTumor TargetingBiomedical EngineeringAdvanced Hepatocellular CarcinomaPharmacologyRadiation OncologyDoxorubicin-loaded Nanoparticles